Metabolomics in the clinic: A review of the shared and unique features of untargeted metabolomics for clinical research and clinical testing
Metabolomics in the clinic: A review of the shared and unique features of untargeted metabolomics for clinical research and clinical testing
复制标题
DOI：
10.1002/jms.4292
复制
发表时间：
2018-11-01
影响因子：
2.3
通讯作者：
Pappan, Kirk L.
中科院分区：
文献类型：
--
作者：
Kennedy, Adam D.;Wittmann, Bryan M.;Pappan, Kirk L.
十多年来，代谢组学一直有望通过提供强大的诊断测试来改变医学实践。然而，现实情况是，由于在高度监管的环境中开发、验证和采用复杂的多变量测试策略带来的巨大挑战，精准医学的发展速度比最初预期的要慢。在本期中，Kennedy及其同事提出了他们对临床测试中非靶向代谢组学未来的愿景。他们强调了测试设计，准确和精确的数据采集，质量控制，数据处理和生化途径分析的复杂性，当在一个单一的临床样本中测量数百至数千种独特的代谢物时。作者概述了（基于质谱的）代谢组学的现状，并说明了这种快速发展的前景的潜力和挑战。
For over a decade, metabolomics has been promising to transform the practice of medicine by delivering powerful diagnostic tests. The reality, however, is that the march towards precision medicine has been slower than first anticipated because of the substantial challenges associated with the development, validation and adoption of complex multivariate testing strategies within a highly regulated environment. In this issue, Kennedy and colleagues present their vision for the future of untargeted metabolomics in clinical testing. They highlight the complexities of test design, accurate and precise data acquisition, quality control, data processing and biochemical pathway analysis when hundreds to thousands of unique metabolites are measured in a single clinical sample. The authors outline the current state of (mass spectrometry-based) metabolomics and illustrate the both the potential, and the challenges, of this rapidly evolving landscape.